Biosimilar CT-P6 tested against herceptin in healthy volunteers
NCT ID NCT06687928
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial compared a single dose of CT-P6, a biosimilar of the cancer drug trastuzumab, to the approved Herceptin in 200 healthy men. The goal was to see if the two drugs behave similarly in the body and have comparable safety. Results will help determine if CT-P6 can be used as a more affordable alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT-P6 (a biosimilar of trastuzumab) and Herceptin (trastuzumab)
What this could lead to
If successful, this could show that CT-P6 works similarly to Herceptin, potentially offering a more affordable treatment option for certain cancers.
What could go wrong
This is an early-phase study in healthy men, not patients. It only checks how the drug moves through the body and safety, not whether it treats disease. Results may not predict real-world effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celltrion
Yeonsu-gu, Incheon, 22006, South Korea